Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of MDM2 in subconfluent U2OS cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 3% BSA for 15 minutes at room temperature. The cells were probed with a MDM2 Mouse Monoclonal Antibody (33-7100) at 1.5 µg/mL for 1 hour at room temperature and then labeled with a Goat anti-Mouse IgG (H+L) Superclonal Secondary Antibody, Alexa Fluor 488 conjugate (Product # A28175) at a dilution of 1:400 for 30 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with Hoechst Dye. F-actin (Panel c: red) was stained with DyLight 554 Phalloidin (Product # 21834). Panel d is a merged image showing predominantly nuclear localization. Panel e shows no primary antibody control. The images were captured at 20X magnification.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b, kappa|
|Immunogen||Synthetic peptide derived from the n-terminal region of human MDM2|
|Storage buffer||PBS, pH 7.4, with 1mg/ml BSA, 30% glycerol|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||1-2 ug/ml|
|Immunofluorescence (IF)||1-2 ug/ml|
|Immunohistochemistry (IHC)||Assay Dependent|
|Immunoprecipitation (IP)||Assay Dependent|
|Western Blot (WB)||2-3 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody recognizes the ~90 kDa (apparent MW) MDM2 protein. Also recognizes isoforms at ~57 and ~74/76 kDa.
MDM2 is a target of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of MDM2 can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report.
33-7100 was used in immunohistochemistry - paraffin section to characterize a primary myxoid liposarcoma with chondroid and osseous components
|Weingertner N,Neuville A,Chibon F,Ray-Coquard I,Marcellin L,Ghnassia JP||Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry (23:230)||2015|
Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.
33-7100 was used in western blot to report proof-of-principle studies targeting CDH7 for treating gastric cancer.
|Qiu HB,Zhang LY,Ren C,Zeng ZL,Wu WJ,Luo HY,Zhou ZW,Xu RH||PloS one (8:null)||2013|
MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
||Yoshida A,Ushiku T,Motoi T,Beppu Y,Fukayama M,Tsuda H,Shibata T||The American journal of surgical pathology (36:423)||2012|
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors.
||Binh MB,Garau XS,Guillou L,Aurias A,Coindre JM||American journal of clinical pathology (125:693)||2006|
MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.
||Khor LY,Desilvio M,Al-Saleem T,Hammond ME,Grignon DJ,Sause W,Pilepich M,Okunieff P,Sandler H,Pollack A||Cancer (104:962)||2005|
Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
||Wang YC,Lin RK,Tan YH,Chen JT,Chen CY,Wang YC||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (23:154)||2005|
HDMX, ACTFS, hdm2
E3 ubiquitin-protein ligase Mdm2, Mdm2, p53 E3 ubiquitin protein ligase homolog, Mdm2, transformed 3T3 cell double minute 2, p53 binding protein, double minute 2, human homolog of; p53-binding protein, oncoprotein Mdm2, HDMX, MGC5370, MGC71221, hdm2